Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
出版年份 2021 全文链接
标题
Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-05-13
DOI
10.1038/s41598-021-89684-5
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells
- (2019) Qingbin Cui et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
- (2019) Kazuki Okubo et al. CANCER SCIENCE
- Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia
- (2017) Jonathan A. Webster et al. LEUKEMIA RESEARCH
- Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor
- (2017) Ryan Montano et al. Oncotarget
- Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement
- (2016) Matthew I. Milowsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells
- (2016) Kathleen A. Bridges et al. Oncotarget
- Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors
- (2015) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
- (2015) Ching-Chia Li et al. Oncotarget
- Biology of the cell cycle inhibitor p21CDKN1A: molecular mechanisms and relevance in chemical toxicology
- (2014) Ilaria Dutto et al. ARCHIVES OF TOXICOLOGY
- Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors
- (2014) W-T Wang et al. ONCOGENE
- ColonyArea: An ImageJ Plugin to Automatically Quantify Colony Formation in Clonogenic Assays
- (2014) Camilo Guzmán et al. PLoS One
- Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo
- (2013) Ryan Montano et al. BMC CANCER
- The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
- (2013) Y. Dai et al. MOLECULAR CANCER THERAPEUTICS
- p21 promotes error-free replication-coupled DNA double-strand break repair
- (2012) Maurizio Mauro et al. NUCLEIC ACIDS RESEARCH
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- The DNA Damage Response: Making It Safe to Play with Knives
- (2010) Alberto Ciccia et al. MOLECULAR CELL
- Comparison of nonhomologous end joining and homologous recombination in human cells
- (2008) Z MAO et al. DNA REPAIR
- Single-strand break repair and genetic disease
- (2008) Keith W. Caldecott NATURE REVIEWS GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started